BRPI1013201A2 - meios e métodos para reconhecer o desenvolvimento de doenças cardiovascular em um indivíduo - Google Patents

meios e métodos para reconhecer o desenvolvimento de doenças cardiovascular em um indivíduo

Info

Publication number
BRPI1013201A2
BRPI1013201A2 BRPI1013201A BRPI1013201A BRPI1013201A2 BR PI1013201 A2 BRPI1013201 A2 BR PI1013201A2 BR PI1013201 A BRPI1013201 A BR PI1013201A BR PI1013201 A BRPI1013201 A BR PI1013201A BR PI1013201 A2 BRPI1013201 A2 BR PI1013201A2
Authority
BR
Brazil
Prior art keywords
individual
iam
recognizing
development
methods
Prior art date
Application number
BRPI1013201A
Other languages
English (en)
Inventor
Sahar Eli
Domany Eytan
R Cohen Irun
Shental Noam
Original Assignee
Yeda res & development co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda res & development co ltd filed Critical Yeda res & development co ltd
Publication of BRPI1013201A2 publication Critical patent/BRPI1013201A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

meio_s e niétodos para reconhecer o desenvolvimento de doenças cardiovasculares em um individuo. um método para reconhecimento de um processo de infarto agudo do s miocárdio (iam) em um indivrduo, onde o método compreende passos de: perfis específicos de anticorpos reativos ou biomarcadores associados com a suscetibilidade a um iam, o perfil compreendendo passos de: anexando um conjunto de antígenos definidos a um substrato; obtendo um fluido biológico de espécie derivada de um indivíduo, este espécime contendo um repertório de anticorpos específicos; e ligando 10 os referidos anticorpos do e~pécime do fluido biológico ao antígeno anexado formando assim uma ligação de complexos de antígenos dos anticorpos; e analisando resultados obtidos, onde a presença dos complexos indicam o iam.
BRPI1013201A 2009-05-05 2010-05-05 meios e métodos para reconhecer o desenvolvimento de doenças cardiovascular em um indivíduo BRPI1013201A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17547209P 2009-05-05 2009-05-05
PCT/IL2010/000361 WO2010128506A2 (en) 2009-05-05 2010-05-05 Means and methods for recognizing the development of cardiovascular disease in an individual

Publications (1)

Publication Number Publication Date
BRPI1013201A2 true BRPI1013201A2 (pt) 2019-02-26

Family

ID=43050575

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013201A BRPI1013201A2 (pt) 2009-05-05 2010-05-05 meios e métodos para reconhecer o desenvolvimento de doenças cardiovascular em um indivíduo

Country Status (6)

Country Link
US (2) US20120122720A1 (pt)
EP (1) EP2427767A4 (pt)
CN (1) CN102803965A (pt)
BR (1) BRPI1013201A2 (pt)
CA (1) CA2760903A1 (pt)
WO (1) WO2010128506A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011213923A1 (en) 2010-02-12 2012-08-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Diagnosis of systemic lupus erythematosus (SLE)
WO2012058598A1 (en) * 2010-10-29 2012-05-03 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating hyperlipidemia or atherosclerosis
US8652999B1 (en) 2012-07-24 2014-02-18 Dow Agrosciences, Llc. Herbicidal compositions comprising 4-amino-3-chloro-5-fluoro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid or a derivative thereof and a sulfonylaminocarbonyltriazolinone
US20160320384A1 (en) 2013-12-31 2016-11-03 Yeda Research And Development Co. Ltd. Methods for assaying immunological competence
WO2015101988A1 (en) 2013-12-31 2015-07-09 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
CN104688187A (zh) * 2015-02-14 2015-06-10 袁玉香 心血管疾病检测装置
EP3265814B1 (en) 2015-03-01 2020-11-18 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0792165A (ja) * 1993-09-21 1995-04-07 Hoechst Japan Ltd 骨粗鬆症診断剤
AU2001237068A1 (en) * 2000-02-18 2001-08-27 Jagat Narula Detection of microbial deposition and immune response at the basement membrane
AU2003270560A1 (en) * 2002-09-11 2004-04-30 Emory University Methods of assessing endothelial dysfunction using acute transient response following fat administration
ES2239532B1 (es) * 2004-02-06 2006-11-01 Proyecto De Biomedicina Cima S.L. Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr.
US20070218498A1 (en) * 2005-08-30 2007-09-20 Buechler Kenneth F Use of soluble FLT-1 and its fragments in cardiovascular conditions
CA2637253A1 (en) * 2006-01-25 2007-08-02 F. Hoffmann-La Roche Ag Anti-troponin antibodies and cardiovascular risk
ES2402334T3 (es) * 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
US9140701B2 (en) * 2009-08-18 2015-09-22 The Board Of Trustees Of The Leland Stanford Junior University Fibrinogen immune complexes to diagnose and guide therapy in rheumatoid arthritis

Also Published As

Publication number Publication date
EP2427767A2 (en) 2012-03-14
WO2010128506A2 (en) 2010-11-11
CA2760903A1 (en) 2010-11-11
CN102803965A (zh) 2012-11-28
US20140336077A1 (en) 2014-11-13
US20120122720A1 (en) 2012-05-17
EP2427767A4 (en) 2013-01-23
US9075072B2 (en) 2015-07-07
WO2010128506A3 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
BRPI1013201A2 (pt) meios e métodos para reconhecer o desenvolvimento de doenças cardiovascular em um indivíduo
MX2009013388A (es) Analisis multiple de muestras de sangre.
WO2006126008A3 (en) Improved immunoassay methods
HRP20201856T1 (hr) Antitijela koja se vežu za ljudski ligand i programiranje smrti (pd-l1)
NZ609363A (en) Methods for determining anti-drug antibody isotypes
NO20076662L (no) Deteksjon av et malantigen uavhengig av tilstedevaerelse eller fravaer av et korresponderende terapeutisk antistoff
EP1996940A4 (en) DETECTION OF CANCER DUE TO INCREASED BCL-2 CONCENTRATIONS
CA2844033C (en) Method for detecting pancreatic cancer
MX2009009448A (es) Sensibilidad mejorada de determinacion de perfil de anticuerpos a traves de una colocacion en capas incrementada de anticuerpo reportero.
WO2010049672A3 (en) Methods and products for measuring free immunoglobulin light chain molecules
EP4524571A3 (en) Assay for jc virus antibodies
JP2012073260A5 (pt)
ATE516501T1 (de) Verfahren für die fluoreszenz-detektion einer substanz
NZ609824A (en) Immunochromatography devices, methods and kits
JP2009539082A5 (pt)
EA200971123A1 (ru) Мультиплексный способ выявления инфекции
JP2013072663A5 (pt)
JP2016532126A5 (pt)
WO2008034102A3 (en) Surface mapping by optical manipulation of particles in relation to a functionalized surface
TW200604527A (en) An immunological method and reagent for determing the inhibited nonspecific reaction
WO2011008831A3 (en) Mass tags for spectrometric analysis of immunoglobulins
EA201370030A1 (ru) Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням
ATE519116T1 (de) Verfahren zur normierung der konzentration von analyten in einer urinprobe
FI20115785A0 (fi) Menetelmä ja laite automaattiseen analyysiin
JP2010006774A5 (pt)

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/175,472 DE 05/05/2009 REIVINDICADA NO PCT/IL2010/000361, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT (?YEDA RESEARCH AND DEVELOPMENT CO. LTD.?) SER DISTINTO DAQUELE QUE DEPOSITOU A PRIORIDADE REIVINDICADA E NAO FOI APRESENTADO O DOCUMENTO COMPROBATORIO DE CESSAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 2 DA RESOLUCAO INPI-PR 179/2017.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2514 DE 12-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]